Infectious Disease Vaccines Market Size to Hit USD 72.40 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Infectious Disease Vaccines Market

5.1. COVID-19 Landscape: Infectious Disease Vaccines Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Infectious Disease Vaccines Market, By Technology

8.1. Infectious Disease Vaccines Market Revenue and Volume, by Technology

8.1.1. Live Attenuated Vaccines

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Inactivated Vaccines

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Subunit, Recombinant, Polysaccharide & Conjugate Vaccines

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Toxoid Vaccines

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. mRNA Vaccines

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Viral Vector Vaccines

8.1.6.1. Market Revenue and Volume Forecast

8.1.7. DNA Vaccines

8.1.7.1. Market Revenue and Volume Forecast

8.1.8. Others

8.1.8.1. Market Revenue and Volume Forecast

Chapter 9. Global Infectious Disease Vaccines Market, By Disease Indication

9.1. Infectious Disease Vaccines Market Revenue and Volume, by Disease Indication

9.1.1. Influenza

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Hepatitis (A, B, E)

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Human Papillomavirus (HPV)

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Mobile

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Tuberculosis

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Meningococcal Disease

9.1.6.1. Market Revenue and Volume Forecast

9.1.7. Pneumococcal Disease

9.1.7.1. Market Revenue and Volume Forecast

9.1.8. Rotavirus

9.1.8.1. Market Revenue and Volume Forecast

9.1.9. Measles, Mumps, Rubella (MMR)

9.1.9.1. Market Revenue and Volume Forecast

9.1.10. COVID-19

9.1.5.10.1 Market Revenue and Volume Forecast

9.1.11. Dengue

9.1.11.1. Market Revenue and Volume Forecast

9.1.12 Malaria

9.1.12.1. Market Revenue and Volume Forecast

9.1.13. HIV/AIDS

9.1.13.1. Market Revenue and Volume Forecast

9.1.14. Others

9.1.14.1. Market Revenue and Volume Forecast

Chapter 10. Global Infectious Disease Vaccines Market, By Age Group

10.1. Infectious Disease Vaccines Market Revenue and Volume, by Age Group

10.1.1. Pediatric

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Adults

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Geriatric

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Infectious Disease Vaccines Market, By End Use

11.1. Infectious Disease Vaccines Market Revenue and Volume, by End Use

11.1.1. Hospitals & Clinics

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Research Institutes

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Government Immunization Programs

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Others

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Infectious Disease Vaccines Market, By Distribution Channel

12.1. Infectious Disease Vaccines Market Revenue and Volume, by Distribution Channel

12.1.1. Public (Government & NGO-led Programs)

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Private (Pharmacies, Hospitals, Clinics)

12.1.2.1. Market Revenue and Volume Forecast

Chapter 13. Global Infectious Disease Vaccines Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Technology

13.1.2. Market Revenue and Volume Forecast, by Disease Indication

13.1.3. Market Revenue and Volume Forecast, by Age Group

13.1.4. Market Revenue and Volume Forecast, by End Use

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Technology

13.1.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.1.6.3. Market Revenue and Volume Forecast, by Age Group

13.1.6.4. Market Revenue and Volume Forecast, by End Use

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Technology

13.1.7.2. Market Revenue and Volume Forecast, by Disease Indication

13.1.7.3. Market Revenue and Volume Forecast, by Age Group

13.1.7.4. Market Revenue and Volume Forecast, by End Use

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Technology

13.2.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.3. Market Revenue and Volume Forecast, by Age Group

13.2.4. Market Revenue and Volume Forecast, by End Use

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Technology

13.2.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.6.3. Market Revenue and Volume Forecast, by Age Group

13.2.7. Market Revenue and Volume Forecast, by End Use

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Technology

13.2.9.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.9.3. Market Revenue and Volume Forecast, by Age Group

13.2.10. Market Revenue and Volume Forecast, by End Use

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Technology

13.2.12.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.12.3. Market Revenue and Volume Forecast, by Age Group

13.2.12.4. Market Revenue and Volume Forecast, by End Use

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Technology

13.2.14.2. Market Revenue and Volume Forecast, by Disease Indication

13.2.14.3. Market Revenue and Volume Forecast, by Age Group

13.2.14.4. Market Revenue and Volume Forecast, by End Use

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Technology

13.3.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.3. Market Revenue and Volume Forecast, by Age Group

13.3.4. Market Revenue and Volume Forecast, by End Use

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Technology

13.3.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.6.3. Market Revenue and Volume Forecast, by Age Group

13.3.6.4. Market Revenue and Volume Forecast, by End Use

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Technology

13.3.8.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.8.3. Market Revenue and Volume Forecast, by Age Group

13.3.8.4. Market Revenue and Volume Forecast, by End Use

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Technology

13.3.10.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.10.3. Market Revenue and Volume Forecast, by Age Group

13.3.10.4. Market Revenue and Volume Forecast, by End Use

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Technology

13.3.11.2. Market Revenue and Volume Forecast, by Disease Indication

13.3.11.3. Market Revenue and Volume Forecast, by Age Group

13.3.11.4. Market Revenue and Volume Forecast, by End Use

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Technology

13.4.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.3. Market Revenue and Volume Forecast, by Age Group

13.4.4. Market Revenue and Volume Forecast, by End Use

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Technology

13.4.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.6.3. Market Revenue and Volume Forecast, by Age Group

13.4.6.4. Market Revenue and Volume Forecast, by End Use

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Technology

13.4.8.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.8.3. Market Revenue and Volume Forecast, by Age Group

13.4.8.4. Market Revenue and Volume Forecast, by End Use

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Technology

13.4.10.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.10.3. Market Revenue and Volume Forecast, by Age Group

13.4.10.4. Market Revenue and Volume Forecast, by End Use

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Technology

13.4.11.2. Market Revenue and Volume Forecast, by Disease Indication

13.4.11.3. Market Revenue and Volume Forecast, by Age Group

13.4.11.4. Market Revenue and Volume Forecast, by End Use

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Technology

13.5.2. Market Revenue and Volume Forecast, by Disease Indication

13.5.3. Market Revenue and Volume Forecast, by Age Group

13.5.4. Market Revenue and Volume Forecast, by End Use

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Technology

13.5.6.2. Market Revenue and Volume Forecast, by Disease Indication

13.5.6.3. Market Revenue and Volume Forecast, by Age Group

13.5.6.4. Market Revenue and Volume Forecast, by End Use

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Technology

13.5.8.2. Market Revenue and Volume Forecast, by Disease Indication

13.5.8.3. Market Revenue and Volume Forecast, by Age Group

13.5.8.4. Market Revenue and Volume Forecast, by End Use

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 14. Company Profiles

14.1. Modern

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Sanofi Pasteur

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. CSL Limited (Seqirus)

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Biological E Limited

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. CanSino Biologics

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Sinovac Biotech,

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. CureVac,

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. GlaxoSmithKline (GSK)

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Johnson & Johnson (Janssen)

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Valneva

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The infectious disease vaccines market size is expected to increase from USD 36.25 billion in 2024 to USD 72.40 billion by 2034.

The infectious disease vaccines market is expected to grow at a compound annual growth rate (CAGR) of around 7.17% from 2025 to 2034.

The major players in the infectious disease vaccines market include Pfizer, Moderna, Johnson & Johnson (Janssen), GlaxoSmithKline (GSK), Sanofi Pasteur, Merck & Co., AstraZeneca, Novavax, Bharat Biotech, Serum Institute of India, CSL Limited (Seqirus), Daiichi Sankyo, Mitsubishi Tanabe Pharma, Biological E Limited, Sinovac Biotech, CanSino Biologics, Zydus Lifesciences, CureVac, Inovio Pharmaceuticals, Valneva

The driving factors of the infectious disease vaccines market are the increased prevalence of infectious diseases and advancements in vaccine technology are driving the global market. The government initiatives and support are further contributing to the market growth.

Asia Pacific region will lead the global infectious disease vaccines market during the forecast period 2025 to 2034.